KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Treasury Shares (2019 - 2025)

Adaptive Biotechnologies' Treasury Shares history spans 7 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 47.35% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, down 47.35%, while the annual FY2025 figure was $5.4 million, 39.83% up from the prior year.
  • Treasury Shares for Q4 2025 was $5.4 million at Adaptive Biotechnologies, down from $11.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $12.0 million in Q1 2024 and bottomed at $651649.0 in Q1 2021.
  • The 5-year median for Treasury Shares is $5.5 million (2022), against an average of $6.3 million.
  • The largest annual shift saw Treasury Shares surged 28862.18% in 2021 before it plummeted 82.58% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $1.2 million in 2021, then soared by 393.87% to $6.0 million in 2022, then surged by 61.65% to $9.7 million in 2023, then grew by 5.23% to $10.2 million in 2024, then plummeted by 47.35% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Treasury Shares are $5.4 million (Q4 2025), $11.5 million (Q3 2025), and $5.4 million (Q2 2025).